C-reactive protein and outcome after ischemic stroke

Stroke

Volumn 30, Issue 5, 1999, Pages 981-985

  Muir, Keith W ^a,c   Weir, Christopher J ^a,b   Alwan, Wafa ^a   Squire, Iain B ^a   Lees, Kennedy R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Acute phase reaction; C reactive protein; Cerebrovascular disorders; Inflammation; Prognosis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK FACTOR; STROKE; SURVIVAL RATE; SURVIVAL TIME;

EID: 0032921864     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.5.981     Document Type: Article

References (24)

1. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990;65:168-172.
2. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
3. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331: 417-424.
4. Pietila KO, Harmoinen AP, Jokinitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients after thrombolytic treatment. Eur Heart J. 1996;17:1345-1349.
5. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-1065.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
7. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
8. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
9. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-428.
10. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
11. Brott T, Adams HP Jr, Olinger CP, Marier JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
12. Kendrick S, Clarke J. The Scottish record linkage system. Health Bull (Edinb). 1993;51:1-15.
13. Isles CG, Walker LM, Beevers GD, Brown I, Cameron HL, Clarke J, Hawthorne V, Hole D, Lever AF, Robertson JW, Wapshaw JA. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens. 1986;4: 141-156.
14. Shepherd J, Cobbe SM, Lorimer AR, McKillop J, Ford I, Packard C, MacFarlane P, Isles C. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epidemiol. 1995;48: 1441-1452.
15. Shepherd J, Cobbe SM, Ford I, Isles CA, Lorimer AR, MacFarlane PW, McKillop JH, Packard C. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307.
16. Bamford J, Dennis M, Sandercock P, Burn J, Warlow C. The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry. 1990;53:824-829.
17. Rothwell NJ, Relton JK. Involvement of cytokines in acute neurodegeneration in the CNS. Neurosci Biobehav Rev. 1993;17:217-227.
18. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke. 1994;25:869-875.
19. Jiang N, Moyle M, Soule HR, Rote WE, Chopp M. Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats. Ann Neurol. 1995; 38:935-942.
20. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995; 37:800-805.
21. Carr S, Farb A, Pearce WH, Virmani R, Yao JS. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg. 1996;23: 755-765, discussion 765-766.
22. Weiss G, Willeit J, Kiechl S, Fuchs D, Jarosch E, Oberhollenzer F, Reibnegger G, Tilz GP, Gerstenbrand F, Wachter H. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis. 1994;106: 263-271.
23. Salomon RN, Underwood R, Doyle MV, Wang A, Libby P. Increased apolipoprotein E and c-fms gene expression without elevated interleukin 1 or 6 mRNA levels indicates selective activation of macrophage functions in advanced human atheroma. Prac Natl Acad Sci U S A. 1992;89:2814-2818.
24. Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Maiwald M, Rohlfs M, Suhr H, Fiehn W, Becher H, Hacke W. Recent infection as a risk factor for cerebrovascular ischemia. Stroke. 1995;26:373-379.